Related Experiment Video
Updated: May 3, 2026

Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
Modifying tumor-associated macrophages: An important adjunct to immunotherapy
Zvi G Fridlender1, Steven M Albelda2
1Institute of Pulmonary Medicine; Hadassah-Hebrew University Medical Center; Jerusalem, Israel ; Thoracic Oncology Laboratory; University of Pennsylvania; Philadelphia, PA USA.
Modulating tumor-associated macrophages (TAMs) significantly enhances immunotherapy effectiveness by altering the tumor microenvironment. TAM-activating agents represent a promising addition to immunotherapy strategies in clinical trials.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Immunotherapy efficacy relies on modifying the tumor microenvironment and overcoming immunosuppression.
- Tumor-associated macrophages (TAMs) are key players within the tumor microenvironment.
- TAMs play a critical role in regulating the immune response within tumors.
Purpose of the Study:
- To investigate the impact of modulating tumor-associated macrophages (TAMs) on immunotherapy outcomes.
- To determine if targeting TAMs can enhance the efficacy of cancer treatments.
- To explore the potential of TAM-activating agents as adjuncts to immunotherapy.
Main Methods:
- The study focused on analyzing the role of TAMs in the tumor microenvironment.
- Methods involved modulating TAM populations and assessing their effects.
- Immunotherapy efficacy was evaluated in conjunction with TAM modulation strategies.
Main Results:
- Modulating TAMs was shown to significantly improve the effectiveness of immunotherapy.
- Targeting TAMs led to a marked augmentation of anti-tumor immune responses.
- Specific alterations in the tumor microenvironment were observed following TAM modulation.
Conclusions:
- Modulating TAMs is a viable strategy to enhance immunotherapy.
- TAM-activating agents hold promise for improving clinical outcomes in cancer patients.
- Future clinical trials should consider incorporating TAM-modulating agents alongside immunotherapy.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment

